-
New analysis shows Novartis Entresto improves glycemic control among heart failure patients with dia
cphi-online
March 21, 2017
New use of insulin was also reduced by 29% among patients taking Entresto compared to enalapril-treated patients.
-
FDA approves Novartis' Kisqali as first-line treatment for HR+/HER2- metastatic breast cancer
cphi-online
March 20, 2017
Kisqali plus letrozole showed treatment benefit across all patient subgroups regardless of disease burden or tumour location.
-
Novartis’ Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a tre
europeanpharmaceuticalreview
March 16, 2017
Novartis announced a new analysis showing that moderate-to-severe psoriasis patients treated with Cosentyx (secukinumab) rapidly regain clear or almost clear skin (Psoriasis Area Severity Index, PASI 90 to 100) following relapse during a treatment pause.
-
Novartis' Kisqali garners FDA approval as first-line breast cancer treatment
firstwordpharma
March 15, 2017
The FDA approved Novartis' Kisqali (ribociclib) in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor positive, HER2-negative advanced or metastatic breast cancer.
-
Sandoz announces winners of inaugural Healthcare Access Challenge #SandozHACk
worldpharmanews
March 14, 2017
Sandoz, a Novartis Division, announced today the three winners of the inaugural Healthcare Access Challenge (Sandoz HACk).
-
Novartis’ Kisqali? Receives FDA Approval as First-Line Treatment for HR+/HER2- Metastatic Breast Can
americanpharmaceuticalreview
March 14, 2017
The US Food and Drug Administration (FDA) has approved Kisqali? (ribociclib, formerly known as LEE011) in combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor positive, huma
-
Novartis' Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a tre
cphi-online
March 09, 2017
Cosentyx has shown superior and sustained results versus both Stelara and Enbrel, delivering long-lasting clear or almost clear skin.
-
Novartis receives positive CHMP opinion for lung cancer combination
europeanpharmaceuticalreview
February 28, 2017
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion.
-
Novartis receives positive CHMP opinion for Tafinlar + Mekinist in BRAF-positive NSCLC patients
cphi-online
February 28, 2017
If approved, Tafinlar + Mekinist will be the first targeted therapy specifically for NSCLC patients with a BRAF V600 mutation.
-
Novartis drug Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastat
worldpharmanews
February 24, 2017
Novartis today announced that the US Food and Drug Administration (FDA) accepted the Company's supplemental New Drug Application (sNDA) for filing.
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight January 2025
